Market Summary: The global market for bifurcation lesions reached a size of USD 624 million in 2022 and is expected to reach USD 888.2 million by 2032, with a projected revenue compound annual growth rate (CAGR) of 4% during the forecast period. The growth is primarily driven by factors such as the increasing prevalence of cardiovascular diseases, a growing demand for minimally invasive procedures, and advancements in medical equipment technology.

Cardiovascular illnesses, particularly Coronary Artery Disease (CAD), remain a leading global cause of death. In 2019, CAD was responsible for 17.9 million deaths, accounting for 32% of all global fatalities according to the World Health Organization (WHO).

Bifurcation lesions occur when an artery divides into two smaller channels, potentially obstructing blood flow and oxygen supply to the heart. The rising incidence of CAD and bifurcation lesions has led to a demand for more efficient treatment options. Minimally invasive techniques are preferred for treating bifurcation lesions due to their lower risk of complications, shorter hospital stays, and quicker recovery. Common treatment methods for bifurcation lesions include Percutaneous Coronary Intervention (PCI) and Drug-Eluting Stents (DES). Furthermore, advancements in medical equipment technology, such as specialized stents designed for bifurcation cases, are expected to drive market growth.

Get a sample copy of the Bifurcation Lesions Market report: https://www.reportsanddata.com/download-free-sample/7203

Key Insights: Type Outlook:

  • True bifurcation lesions occur when an artery divides into two branches, requiring treatment for both. Specialized equipment like customized bifurcation stents and balloons are often used for such cases. The demand for genuine bifurcation lesion therapy is expected to rise due to an increase in PCI procedures and CAD prevalence.
  • Non-true bifurcation lesions involve treating only one branch of a blood vessel, making them less complex. The non-true bifurcation lesions market is expected to grow steadily due to the expanding use of PCI treatments.
  • Technological advancements and imaging technologies like Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) are likely to further boost the true bifurcation lesions segment's growth.

Treatment Outlook:

  • Drug-eluting stents (DES) are specialized stents coated with medications to prevent restenosis. They are considered the gold standard for bifurcation lesion treatment due to their effectiveness in preventing restenosis and coverage of both bifurcation branches.
  • Bare-metal stents (BMS) are uncoated stents used to keep blood vessels open. While BMS are effective in reducing short-term problems, DES are preferred due to their lower restenosis risk.
  • Balloon angioplasty is a minimally invasive procedure for non-complex bifurcation lesions and is expected to grow at a faster rate than overall treatment methods.
  • Coronary artery bypass grafting (CABG) is a surgical option for complex bifurcation lesions, often recommended for patients ineligible for PCI.
  • The "Others" segment includes alternative therapies such as rotating atherectomy, cutting balloon angioplasty, and laser angioplasty, which may be used for difficult bifurcation lesions.

Regional Outlook:

  • The North American market for bifurcation lesions is the largest due to the high prevalence of cardiovascular diseases (CVDs) and a strong healthcare infrastructure. Awareness campaigns also contribute to market expansion.
  • Europe is the second-largest regional market, driven by advanced medical technology, aging populations, and increased CVD awareness.
  • Asia Pacific is expected to experience the fastest growth, primarily due to the rising incidence of CVDs, increased disposable income, and healthcare infrastructure improvements. China and India are significant contributors to this growth.
  • South America, the Middle East, and Africa are also expected to see significant growth, thanks to advanced medical technologies and the adoption of minimally invasive surgeries, along with increasing disease awareness.

Competitive Landscape:

  • Major players in the bifurcation lesions market include Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Medtronic plc, Terumo Corporation, Cook Medical LLC, BIOTRONIK SE & Co. KG, C. R. Bard, Inc., and Endologix, Inc.

Strategic Developments:

  • Several key players have announced innovative products for treating bifurcation lesions, including Medtronic's Sola Vascular Self-Expanding Stent System, Abbott Laboratories' acquisition of Walk Vascular, Boston Scientific Corporation's Ranger Drug-Coated Balloon, and Terumo Corporation's Ultimaster™ Tansei™ Drug-Eluting Stent System.

New Product Launches:

  • Companies like Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, and Cook Medical LLC have introduced new products to enhance the treatment of bifurcation lesions.

Segments Covered in the Report:

  • The report segments the bifurcation lesions market by type, treatment, and region. It provides historical data and forecasts revenue growth at global, regional, and country levels.

Report Scope:

  • The report covers data from 2022 with a 4% CAGR, projecting a revenue of USD 888.2 million in 2032.
  • Historical data from 2020-2021 and forecasts from 2022-2032.
  • Quantitative units in USD Million.
  • The report includes market trends, segments, and sub-segments, offering insights into the global bifurcation lesions market.

Explore Trending Reports:

Monoethylene Glycol Market-https://www.globenewswire.com/news-release/2019/08/27/1907300/0/en/Monoethylene-Glycol-Market-To-Reach-USD-36-98-Billion-By-2026-Reports-And-Data.html

Heat Stabilizers Market-https://www.globenewswire.com/news-release/2019/10/07/1925992/0/en/Heat-Stabilizers-Market-To-Reach-USD-5-34-Billion-By-2026-Reports-And-Data.html

Low-VOC Coating Additive Market-https://www.globenewswire.com/news-release/2020/05/06/2028445/0/en/Low-VOC-Coating-Additive-Market-To-Reach-USD-8-70-Billion-By-2027-Reports-and-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/7203

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release